文献速递胸部肿瘤

综合基因组图谱分析显示肺肉瘤样癌常携带潜在可靶向的基因组变异或高肿瘤突变负荷

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
PubMed 文献 · J Thorac Oncol · 2017-03-16

对15867例非小细胞肺癌(含125例肺肉瘤样癌,占0.8%)行杂交捕获综合基因组图谱分析,肺肉瘤样癌中TP53变异占74%,KRAS变异占34%,MET外显子14跳跃变异占12%(高于非肺肉瘤样癌的约3%,p<0.0001),高肿瘤突变负荷(>20个突变/Mb)占20%(非肺肉瘤样癌为14%,p=0.056)。多数肺肉瘤样癌存在潜在可靶向变异或中/高肿瘤突变负荷,综合基因组图谱分析或可提供治疗选择。

要点

  • 肺肉瘤样癌中MET外显子14跳跃变异占12%,高于非肺肉瘤样癌的约3%(p<0.0001)。
  • 肺肉瘤样癌高肿瘤突变负荷(>20个突变/Mb)占20%,非肺肉瘤样癌为14%(p=0.056)。
  • 30%的肺肉瘤样癌携带NCCN非小细胞肺癌指南推荐检测基因的潜在可靶向变异。

核心结论

  • 多数肺肉瘤样癌病例存在NCCN非小细胞肺癌基因的潜在可靶向变异(30%)或中/高肿瘤突变负荷(43%,>10个突变/Mb),综合基因组图谱分析用于临床 care 或可为这一历来难以治疗的疾病提供重要治疗选择。

研究设计与样本

  • 对15867例非小细胞肺癌(包括125例肺肉瘤样癌,占0.8%)的福尔马林固定石蜡包埋切片DNA行基于杂交捕获的综合基因组图谱分析。
  • 肿瘤突变负荷由1.11兆碱基(Mb)的测序DNA计算。

主要发现

  • 肺肉瘤样癌患者中位年龄67岁(范围32-87),58%为男性,78%为IV期疾病。
  • 74%的病例检出TP53基因组变异,其基因组特征与TP53野生型病例不同;62%的病例存在KRAS(34%)或NCCN非小细胞肺癌指南目前推荐检测的七个基因之一的变异,包括MET(13.6%)、EGFR(8.8%)、BRAF(7.2%)、HER2(1.6%)和RET(0.8%)。
  • MET外显子14变异在肺肉瘤样癌中富集(12%),高于非肺肉瘤样癌(约3%)(p<0.0001),且在伴有腺癌成分的肺肉瘤样癌病例中更常见。
  • 肺肉瘤样癌中高肿瘤突变负荷(>20个突变/Mb)的比例为20%,非肺肉瘤样癌为14%(p=0.056)。
  • 9例接受靶向或免疫治疗的肺肉瘤样癌患者中,3例部分缓解,3例疾病稳定。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic strategies for PSC has been hampered because of limited and inconsistent molecular characterization. METHODS: Hybrid capture-based comprehensive genomic profiling was performed on DNA from formalin-fixed paraffin-embedded sections of 15,867 NSCLCs, including 125 PSCs (0.8%). Tumor mutational burden (TMB) was calculated from 1.11 megabases (Mb) of sequenced DNA. RESULTS: The median age of the patients with PSC was 67 years (range 32-87), 58% were male, and 78% had stage IV disease. Tumor protein p53 gene (TP53) genomic alterations (GAs) were identified in 74% of cases, which had genomics distinct from TP53 wild-type cases, and 62% featured a GA in KRAS (34%) or one of seven genes currently recommended for testing in the National Comprehensive Cancer Network NSCLC guidelines, including the following: hepatocyte growth factor receptor gene (MET) (13.6%), EGFR (8.8%), BRAF (7.2%), erb-b2 receptor tyrosine kinase 2 gene (HER2) (1.6%), and ret proto-oncogene (RET) (0.8%). MET exon 14 alterations were enriched in PSC (12%) compared with non-PSC NSCLCs (∼3%) (p < 0.0001) and were more prevalent in PSC cases with an adenocarcinoma component. The fraction of PSC with a high TMB (>20 mutations per Mb) was notably higher than in non-PSC NSCLC (20% versus 14%, p = 0.056). Of nine patients with PSC treated with targeted or immunotherapies, three had partial responses and three had stable disease. CONCLUSION: Potentially targetable GAs in National Comprehensive Cancer Network NSCLC genes (30%) or intermediate or high TMB (43%, >10 mutations per Mb) were identified in most of the PSC cases. Thus, the use of comprehensive genomic profiling in clinical care may provide important treatment options for a historically poorly characterized and difficult to treat disease.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Schrock AB, Li SD, Frampton GM, et al. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. J Thorac Oncol. 2017. PMID: 28315738. doi:10.1016/j.jtho.2017.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。